Ewing Sarcoma (Oncology) - Drugs in Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Drugs In Development, 2021, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.
Ewing’s sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing’s sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 28, 11, 1, 27 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 4 and 1 molecules, respectively.
Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
120 pages •
By Infiniti Research Limited
• Dec 2021
Global Bile Duct Cancer Market 2022-2026 The analyst has been monitoring the bile duct cancer market and it is poised to grow by $ 105.55 mn during 2022-2026, progressing at a CAGR of 7.79% during the forecast period. Our report on the bile duct cancer market provides a holistic analysis, market size and forecast, trends,...
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) – Drugs In Development, 2021, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline...
Myelodysplastic Syndrome (MDS) Treatment market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Myelodysplastic Syndrome (MDS) Treatment Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Myelodysplastic Syndrome...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the cancer clinical decision tools market are McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers, Elsevier B.V., Macmillan, and National Decision Support Company. The global cancer clinical decision tools market is expected to grow from $0.36 billion in 2020 to $0.39...
Report Scope: This research report presents an in-depth analysis of the global cancer stem cells market by cancer type and geographic markets.The report includes key inhibitors that affect various factors that help in growth of cancer stem cells. The report discusses the roles of supply chain members from manufacturers...
274 pages •
By Global Industry Analysts
• Jan 2022
Abstract: Global DNA Sequencing Market to Reach US$10.1 Billion by the Year 2026 Deoxyribonucleic acid (DNA) sequencing involves process of determining sequence of four nucleotides bases namely, adenine, cytosine, guanine, and thymine present in DNA. The advanced technology assists healthcare...
Medulloblastoma (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma – Drugs In Development, 2021, provides an overview of the Medulloblastoma (Oncology) pipeline landscape. Medulloblastoma is the most common malignant...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.